Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $679.29M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.29M
Average 0.45M
Returns on capital
Attovia Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-40.2%
avg -52.1%
ROIC
-42.8%
avg -51.5%
ROA
-36.5%
avg -44.2%
Analysis
ROA is currently the strongest return metric at -36.5% versus its period average of -44.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Tao Fu | CEO, President & Director | USD 840.87K | 54 | 23.44K | 0.05% |
Hubert C. Chen | Chief Medical Officer | USD 651.89K | 57 | — | — |
Petter Veiby | Chief Scientific Officer | USD 639.57K | 61 | 140.00K | 0.31% |
Bora Han | VP & Head of Preclinical Development | — | — | — | — |
Hangjun Zhan | Chief Technology Officer | — | 66 | — | — |
Zaneta Odrowaz | Chief Business Officer, Treasurer & Secretary | — | 42 | 140.00K | 0.31% |
Steven Chan | Chief Financial Officer | — | 54 | 80.73K | 0.18% |
Compensation is shown in the reported currency; data updated Nov 18, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 4, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
25
$72.94M
Sells
92
$9.01M
Net Transaction Value
+$63.93M
Net buying
Most Active
GOLDMAN SACHS GROUP INC
56 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 6, 26Aug 6, 2026 | GOLDMAN SACHS GROUP INC Indirect | Buy | $8.5M$8,500,000.00 |
| Aug 6, 26Aug 6, 2026 | GOLDMAN SACHS GROUP INC Indirect | Buy | $8.5M$8,500,000.00 |
| Aug 6, 26Aug 6, 2026 | Frazier Life Sciences XI, L.P. Direct | Buy | $10M$9,999,995.00 |
| Aug 6, 26Aug 6, 2026 | WALSH COLIN Indirect | Buy | $8.5M$8,500,000.00 |
| Aug 6, 26Aug 6, 2026 | WALSH COLIN Indirect | Buy | $8.5M$8,500,000.00 |
| Aug 6, 26Aug 6, 2026 | venBio Global Strategic Fund IV, L.P. Direct | Buy | $6.5M$6,499,984.00 |
| Aug 6, 26Aug 6, 2026 | Redmile Group, LLC Indirect | Buy | $6.8M$6,800,000.00 |
| Aug 6, 26Aug 6, 2026 | Redmile Group, LLC Direct | Buy | $3.4M$3,400,000.00 |
| Aug 6, 26Aug 6, 2026 | Sanofi Indirect | Buy | $5.1M$5,100,000.00 |
| Aug 5, 26Aug 5, 2026 | GOLDMAN SACHS GROUP INC Indirect | Sell | $153.5K$153,549.10 |
1–10 of 117
Summary
Insiders reported 25 buys worth $72.94M and 92 sells worth $9.01M over the last 12 months. That adds up to net buying of $63.93M. GOLDMAN SACHS GROUP INC was the most active insider with 56 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Competitors
Who does Attovia Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ATTO's management, answered from reported figures.
Who manages ATTO?
Attovia Therapeutics, Inc. (ATTO) lists 7 active executives. The top listed executive is Bora Han, VP & Head of Preclinical Development.
Are ATTO insiders buying or selling?
Recent insider activity shows net buying of $95.05M.
Continue the stock analysis
Jump to another research area for this company.